FDA panel recommends Moderna’s mRNA flu shot for older adults

A panel of experts has endorsed Moderna’s innovative mRNA flu shot for older adults, citing its 27% higher effectiveness compared to traditional flu vaccines in late-stage trials. This significant leap in efficacy could offer better protection for one of the most vulnerable populations to severe flu complications. While the FDA and CDC still need to approve the vaccine, this recommendation marks a promising step forward in the ongoing quest for more effective flu prevention methods. The broader implications could reshape flu vaccination strategies and improve public health outcomes.